Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series.

The 10 patients who had not developed recurrence by the end of the study period had serum CA19–9 levels of 7 IU/L (range <2–13 IU/L), but in those patients who had recurrent disease, the serum CA19–9 level showed a clear trend of increase during the post-operative period, and at the time of a documented radiological recurrence, the serum CA19–9 level was 1818 IU/L (range 75–7049 IU/L). 4.

also in 19,460 other papers